The future is psychedelic: Vail Health Innovation Center director’s research digs into psilocybin as a treatment for depression

Ali Longwell | Vail Daily

Vail Health’s Dr. Charles Raison is at the forefront of psilocybin research, both inside and outside of the organization.

The Vail Health Behavioral Health Innovation Center is expected to start its own psilocybin research sometime this summer and will seek to answer some of the outstanding questions from Raison’s study for Usona. The center is calling the psilocybin research the OPT-in study. In contrast to the Usona work, it will not be directly related to the FDA approval of the drug as a treatment for depression. The FDA will regulate the OPT-in study. However, this information will still be “influential” in terms of informing “how to optimally use psilocybin, in this case, for depression,” Raison said.